💞 #Gate Square Qixi Celebration# 💞
Couples showcase love / Singles celebrate self-love — gifts for everyone this Qixi!
📅 Event Period
August 26 — August 31, 2025
✨ How to Participate
Romantic Teams 💑
Form a “Heartbeat Squad” with one friend and submit the registration form 👉 https://www.gate.com/questionnaire/7012
Post original content on Gate Square (images, videos, hand-drawn art, digital creations, or copywriting) featuring Qixi romance + Gate elements. Include the hashtag #GateSquareQixiCelebration#
The top 5 squads with the highest total posts will win a Valentine's Day Gift Box + $1
Recently, a new project in the Crypto Assets market called FHE has emerged, but its current situation is concerning. Observations show that while the project's official social media account has as many as 550,000 followers, the interaction on each tweet is extremely low, with an average of fewer than 20 comments per post. This abnormal phenomenon raises doubts about the authenticity of its fan base.
What is more concerning is that FHE is currently only listed on some relatively niche trading platforms. These platforms generally face issues such as low trading volumes and poor liquidity, which may lead to price manipulation and increase the risks for investors.
From a project operation perspective, FHE seems to lack a clear business model and revenue sources. Currently, the project relies mainly on token sales to maintain operations, and this single income structure raises questions about its long-term sustainability.
Considering all the above factors, investors need to be particularly cautious when contemplating the purchase of FHE. While the low price may seem attractive, the hidden risks cannot be ignored. It is recommended that investors conduct thorough research on the project's background, technological innovation, and team strength to comprehensively assess investment risks before making a decision. Additionally, it is important to closely monitor market dynamics and changes in the regulatory environment to make more informed investment choices.